By Ben Hirschler LONDON (Reuters) – Britain's departure from the European Union would threaten scientific research and jeopardize the 28-nation bloc's system of drug regulation, the European pharmaceutical industry said on Wednesday. The declaration is the clearest statement yet on the issue by an industry that includes EU-based players such as Britain's GlaxoSmithKline and AstraZeneca, France's Sanofi and Germany's Bayer. The European Federation of Pharmaceutical Industries and Associations (EFPIA) said Britain's continued EU membership was in the best interests of a strong life sciences sector both in the UK and across Europe.
View post:
Brexit is the wrong prescription, says European pharma industry
